While further research is needed, liraglutide may work through various mechanisms, such as reducing inflammation in the brain, lowering insulin resistance and the toxic effects of Alzheimers biomarkers amyloid-beta and tau, and improving how the brains nerve cells communicate. Edison added that those in the study who received liraglutide had nearly 50% less volume loss in several areas of the brain, including frontal, temporal, parietal and total gray matter, as measured by MRI
Gastrointestinal effects are the most common
If Phase 3 trials meet efficacy and safety endpoints, Eli Lilly may submit a BLA to the FDA
The FDAs announcement that tirzepatide is no longer in shortage means compounding is now tightly restricted, and pharmacies may only prepare the medication for patients with verifiable clinical need that cannot be met by the FDA-approved formulation
This page explains what it is and how clinician-supervised treatment through ElliotMeds works